ALL Metrics
-
Views
-
Downloads
Get PDF
Get XML
Cite
Export
Track
Brief Report

A snapshot of the ongoing clinical research on COVID-19

[version 1; peer review: 2 approved]
* Equal contributors
PUBLISHED 18 May 2020
Author details Author details
OPEN PEER REVIEW
REVIEWER STATUS

This article is included in the Emerging Diseases and Outbreaks gateway.

This article is included in the Coronavirus (COVID-19) collection.

Abstract

The pandemic of coronavirus disease 2019 (COVID-19) presents an unprecedented challenge to rapidly develop new diagnostic, preventive and therapeutic strategies. Currently, thousands of new COVID-19 patients are quickly enrolled in clinical studies. We aimed to investigate the characteristics of the COVID-19 studies registered in ClinicalTrials.gov and report the extent to which they have incorporated features that are desirable for generating high-quality evidence.
On April 28, 2020, a total of 945 studies on COVID-19 have been registered in ClinicalTrials.gov; 586 studies are interventional (62.0%), the most frequent allocation scheme is the parallel group assignment (437; 74.6%), they are open-label and the most common primary purpose is the research on treatment.
Too many of the ongoing interventional studies have a small expected sample size and may not generate credible evidence at completion. This might lead to a delayed recognition of effective therapies that are urgently needed, and a waste of time and resources. In the COVID-19 pandemic era, it is crucial that the adoption of new diagnostic, preventive and therapeutic strategies is based upon evidence coming from well-designed, adequately powered and carefully conducted clinical trials.

Keywords

SARS-CoV-2, 2019-nCoV, 2019 novel coronavirus, severe acute respiratory syndrome coronavirus 2, Covid-19

Introduction

The pandemic of coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents an unprecedented challenge to rapidly develop new diagnostic, preventive and therapeutic strategies1. Currently, thousands of new COVID-19 patients present for care every day, and many are quickly enrolled in clinical studies. We aimed to investigate the characteristics of the COVID-19 studies registered in ClinicalTrials.gov2, and report the extent to which they have incorporated features that are desirable for generating high-quality evidence.

Methods

We investigated the ClinicalTrials.gov website on April 28, 2020, using the search term: SARS-CoV-2 OR 2019-nCoV OR 2019 novel coronavirus OR severe acute respiratory syndrome coronavirus 2 OR Covid-19. No restrictions were applied. No screening of trials was performed; all results were included regardless of their content.

Stata 15.0 (Stata Corp., College Station, TX, USA) was used for the analysis of study characteristics.

Results

A total of 945 studies on COVID-19 have been registered in ClinicalTrials.gov up to April 29, 2020; 586 studies are interventional (62.0%), and 435 of them (74.2%) are randomized. Among interventional studies, the most frequent allocation scheme is the parallel group assignment (437; 74.6%), followed by single group (111; 18.9%], sequential (18; 3.1%), factorial (9; 1.5%), and cross-over assignment (11; 1.9%). The majority of the clinical trials are open-label (no masking, 338 [57.7%]); however, 57 (9.7%) trials are double-blinded, 41 (7.0%) triple-blinded, 90 (15.4%) quadruple-blinded, and 60 (10.2%) single-blinded. Among observational studies, cohort (222; 64.3%) is the most common study design (Table 1).

Table 1. Characteristics of COVID-19 studies registered in ClinicalTrials.gov (n=945).

Study typeN (%)
Study design (n=945)
   Interventional586 (62.0)
   Observational345 (36.5)
   Expanded access14 (1.5)
Recruitment status (n=945)
   Recruiting or enrolling by invitation453 (47.9)
   Not yet recruiting414 (43.8)
   Active, not recruiting24 (2.5)
   Completed27 (2.9)
   Withdrawn, terminated or suspended13 (1.4)
   Available13 (1.4)
Intervention type (n=945)
   Drug405 (42.9)
   Biological (cells, blood sampling, etc)74 (7.8)
   Diagnostic test60 (6.3)
   Device44 (4.7)
   Procedure18 (1.9)
   Behavioral20 (2.1)
   Dietary supplement9 (1.0)
   Other/Unknown315 (33.3)
Target age (n=945)
   Any age165 (17.5)
   Child (<18 y)5 (0.5)
   Child and adult (<65 y)8 (0.8)
   Adult (18–65 y)35 (3.7)
   Adult and elderly (≥18 y)720 (76.2)
   Elderly (≥66 y)12 (1.3)
Funding (n=945)
   NIH or federal13 (1.4)
   Industry82 (8.7)
   Industry plus other63 (6.7)
   Other (organizations, universities,
   individuals)
787 (83.2)
Expected trial size (n=931)200 (66–504)
   0–100344 (37.0)
   101–1000439 (47.1)
   >1000148 (15.9)
   Interventional (n=586) [median
   (IQR)]
150 (52–420)
   Observational (n=345) [median
   (IQR)]
300 (100–1,000)
Study results (n=945)
   Not available945 (100)
Interventional studies (n=586)
Study phase (n=586)
   Phase 0, 1, 1/262 (10.6)
   Phase 2, 2/3212 (36.2)
   Phase 3, 4165 (28.1)
   Not applicable147 (25.1)
Model (n=586)
   Parallel assignment437 (74.6)
   Single group assignment111 (18.9)
   Sequential18 (3.1)
   Factorial assignment9 (1.5)
   Crossover assignment11 (1.9)
Masking (n=586)
   Open label or no masking338 (57.7)
   Single-blind60 (10.2)
   Double-blind57 (9.7)
   Triple-blind41 (7.0)
   Quadruple-blind90 (15.4)
Study allocation (n=586)
   Randomized435 (74.2)
   Non-randomized53 (9.1)
   Unknown/missing98 (16.7)
Observational studies (n=345)
Observational model (n=345)
   Cohort222 (64.3)
   Case-control34 (9.9)
   Case-only45 (13.0)
   Ecologic or community11 (3.2)
   Other33 (9.6)
Time perspective (n=345)
   Prospective230 (66.7)
   Retrospective58 (16.8)
   Cross-sectional31 (9.0)
   Other26 (7.5)

Most studies target adult or elderly participants, while 178 (18.8%) enroll children, with only five (0.5%) recruiting exclusively children. Median expected study size is 200 (interquartile range, 66–504), although sample sizes vary from ≤100 (344; 37.0%) to >1,000 individuals (148; 15.9%). Overall, only 27 of 945 studies (2.9%) have completed recruitment, 453 (47.9%) are actively recruiting subjects, while a large number of studies (414; 43.8%) are not yet actively recruiting participants. Most of the studies are conducted in Europe (n=327), North America (n=217, of which 186 in the US), East Asia (n=102), Africa (n=27), and in South America (n=26). No study has reported results yet.

Among the interventional studies, the most common primary purpose is the research on treatment (441; 75.3%), followed by prevention (79; 13.5%), supportive care studies (22; 3.8%), and diagnostic investigations (17; 2.9%). Regarding the drugs under scrutiny, hydroxychloroquine (110; 28.6%), azithromycin (38; 9.9%), lopinavir/ritonavir (24; 6.2%), interferon-α and -β (24; 6.2%), glucocorticoids (22; 5.7%), chloroquine (14; 3.6%), favipiravir (10; 2.6%), remdesivir (8; 2.1%), tocilizumab (21; 5.5%), anti-SARS-CoV-2 immunoglobulins (15; 3.9%) and sarilumab (9; 2.3%) account for the majority of interventional studies. Additional details are featured in Table 2.

Table 2. Characteristics of COVID-19 interventional studies registered in ClinicalTrials.gov (n=586).

Study typeNo. (%)
Primary purpose (n=586)
   Treatment441 (75.3)
   Prevention79 (13.5)
   Supportive care22 (3.8)
   Diagnostic17 (2.9)
   Other13 (2.2)
   Screening5 (0.8)
   Basic science5 (0.8)
   Health services research4 (0.7)
Drugs (n=385)
   Repurposed drugs
       Hydroxychloroquine110 (28.6)
       Azithromycin38 (9.9)
       Lopinavir/Ritonavir24 (6.2)
       Glucocorticoids22 (5.7)
       Interferon-α and -β24 (6.2)
       Chloroquine14 (3.6)
       Nitazoxanide8 (2.1)
       Camostat4 (1.0)
       Oseltamivir4 (1.0)
       Ribavirin1 (0.3)
   Investigational agents
       Favipiravir10 (2.6)
       Remdesivir8 (2.1)
   Adjunctive therapies
       Tocilizumab21 (5.5)
       Anti SARS-CoV-2
       immunoglobulins
15 (3.9)
       Sarilumab9 (2.3)

Discussion

Our survey presents the current COVID-19 clinical research landscape. Several hundreds of clinical studies have been initiated all over the globe, and the number is growing. Most interventional studies incorporate randomisation, which is considered the hallmark of high-quality clinical trials3, while more than 40% are blinded.

Studies are being conducted especially in the most affected areas: Europe and US. The number of COVID-19 cases in low to middle-income countries is still relatively low, also reflecting scarce testing, but is expected to rise in the next period. These countries will need more research on organizational measures, and trials on interventions that are affordable and applicable to those settings4.

Most studies focus on adults and elderlies, while only few target children, possibly reflecting the observed burden of the disease. Additional effort is needed to ensure that minors are included in COVID-19 clinical research, so that therapeutic decisions are based upon high-quality evidence.

No drug with proven clinical efficacy currently exists for SARS-CoV-2 infection. Despite the absence of solid evidence, several treatments are being currently used in clinical practice in several countries, with sometimes disastrous consequences5. Too many of the ongoing interventional studies have a small expected sample size, and may not generate credible evidence at completion4. This might lead to a delayed recognition of effective therapies that are urgently needed, and a waste of time and resources. In the COVID-19 pandemic era, it is crucial that the adoption of new diagnostic, preventive and therapeutic strategies is based upon evidence coming from well-designed, adequately powered and carefully conducted clinical trials.

Data availability

The Clinical Trials website can be accessed here: https://clinicaltrials.gov/

Comments on this article Comments (0)

Version 1
VERSION 1 PUBLISHED 18 May 2020
Comment
Author details Author details
Competing interests
Grant information
Copyright
Download
 
Export To
metrics
Views Downloads
F1000Research - -
PubMed Central
Data from PMC are received and updated monthly.
- -
Citations
CITE
how to cite this article
Piovani D, Pansieri C, Peyrin-Biroulet L et al. A snapshot of the ongoing clinical research on COVID-19 [version 1; peer review: 2 approved]. F1000Research 2020, 9:373 (https://doi.org/10.12688/f1000research.23843.1)
NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.

Open Peer Review

Current Reviewer Status: ?
Key to Reviewer Statuses VIEW
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions
Version 1
VERSION 1
PUBLISHED 18 May 2020
Views
9
Cite
Reviewer Report 28 May 2020
Ioannis Mamais, Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens, Greece 
Approved
VIEWS 9
I have read it through, and it seems to be an interesting brief report.

Some comments below: 
  • 74.2% of those studies are mention as "Randomized" and 40% as blinded, from researchers. Authors of this brief
... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Mamais I. Reviewer Report For: A snapshot of the ongoing clinical research on COVID-19 [version 1; peer review: 2 approved]. F1000Research 2020, 9:373 (https://doi.org/10.5256/f1000research.26310.r63547)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
Views
18
Cite
Reviewer Report 26 May 2020
Demetris Lamniosos, Department of Health Sciences, School of Sciences, European University Cyprus, Nicosia, Cyprus 
Approved
VIEWS 18
This brief report is a survey of the current COVID-19 clinical research landscape. The number of clinical studies on COVID-19 is rapidly growing and it is important the investigation of whether these studies are incorporating features that are desirable for ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Lamniosos D. Reviewer Report For: A snapshot of the ongoing clinical research on COVID-19 [version 1; peer review: 2 approved]. F1000Research 2020, 9:373 (https://doi.org/10.5256/f1000research.26310.r63548)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.

Comments on this article Comments (0)

Version 1
VERSION 1 PUBLISHED 18 May 2020
Comment
Alongside their report, reviewers assign a status to the article:
Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
Sign In
If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.

The email address should be the one you originally registered with F1000.

Email address not valid, please try again

You registered with F1000 via Google, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Google account password, please click here.

You registered with F1000 via Facebook, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Facebook account password, please click here.

Code not correct, please try again
Email us for further assistance.
Server error, please try again.